首页|炎症相关靶点及非酒精性脂肪性肝炎治疗的研究进展

炎症相关靶点及非酒精性脂肪性肝炎治疗的研究进展

Exploring Inflammation-Related Targets and Advances in the Treatment of Nonalcoholic Steatohepatitis

扫码查看
原文链接
  • 维普
  • 万方数据
非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)作为非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的重要亚型,逐渐严重威胁全球健康水平.但由于其发病机制复杂,目前尚无针对NASH的上市药物.该疾病不仅涉及脂肪堆积,还伴随着炎症和纤维化过程,其中炎症在NASH的恶化过程中扮演着重要角色,长期的炎症反应,会促进肝纤维化和脂质稳态失衡.因此,抑制炎症对改善NASH具有重要意义.笔者系统地综述丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK),核因子 κB(nuclear factor-KB,NF-KB),非活性菱形蛋白(inactive rhomboid-like protein 2,iRhom2)和炎症小体等炎症信号通路在NASH发展过程中的作用机制,及Selonsertib,SHR0302和漆黄素等相关药物的研究现状,进一步探讨NASH治疗的新靶点研究进展,旨在为治疗NASH药物的研发提供基础.
Non-alcoholic steatohepatitis(NASH),a severe subtype of non-alcoholic fatty liver disease(NAFLD),is emerging as a major health threat worldwide.However,due to its complex pathogenesis,there are currently no marketed drugs for NASH.The dis-ease is not only involved in fat accumulation,but also accompanied by inflammation and fibrosis processes,in which inflammation plays an important role in the progression of NASH,long-term inflammatory response,can promote liver fibrosis and lipid homeostasis imbal-ance.Therefore,inhibiting inflammation is of great significance in improving NASH.This review systematically reviews the mechanism of action of inflammatory signaling pathways such as mitogen-activated protein kinase(MAPK),nuclear factor-κB(NF-κB),inactive rhomboid-like protein 2(iRhom2)and inflammasome in the development of NASH,and the current research status of related drugs such as Selonsertib,SHR0302 and fisetin,and further discusses the research progress of new targets for the treatment of NASH.It aims to provide new ideas for the research and development of drugs for NASH.

nonalcoholic steatohepatitis(NASH)inflammatory signaling pathwaynuclear factor-κB(NF-κB)inactive rhomboid like protein 2(iRhom2)inflammasome

刘鑫、罗娅、徐敏轩、葛晨旭、刘建辉、谭君

展开 >

重庆理工大学药学与生物工程学院,重庆 400054

重庆第二师范学院生物与化学工程学院,重庆 400067

三峡库区药用资源重庆市重点实验室,重庆 400067

非酒精性脂肪性肝炎 炎症信号通路 核因子κB 非活性菱形蛋白2 炎症小体

国家自然科学基金项目资助国家自然科学基金项目资助重庆市自然科学基金创新发展联合基金重点项目资助

8220065281703527CSTB2022NSCQ-LZX0053

2024

10.11669/cpj.2024.13.001

中国药学杂志
中国药学会

中国药学杂志

CSTPCD北大核心
影响因子：0.957
ISSN：1001-2494
年,卷(期)：2024.59(13)